The 6 W’s: Who, what, where, when, why and what of it
RegMed sector stocks are up nearly 2:1 as positive news regarding trials and partnerships create buzz. A good luck day – as investors had been trying to catch their breath a bit since the RegMed sector has been on its knees in the past three (3) months in a row even though the NADAQ has been up so far in the year?
Measuring the day
POSITIVE – 20 green (ups), followed by 12 red (downs) and 5 fluctuating black (flats)
Stocks extended their gains Monday following a better-than-expected pending home sales report and after Italy’s new prime minister named his cabinet over the weekend, ending two months of political deadlock.
The NASDAQ is UP … +28.24 or +0.86% to 3,307.5 while the Dow is also UP +74.29 or +0.50% at 14,786.84. The CBOE volatility index traded below 14.
- RegMed Daily – The Early Movers … http://www.scimitarequity.com/blog/2013/04/29/the-early-movers-whos-hot-whos-not-11
- NeoStem’s (NYSE MKT: NBS) Subsidiary, PCT development agreement …http://www.scimitarequity.com/blog/2013/04/29/neostems-nyse-mkt-nbs-subsidiary-pct-development-agreement
- Aastrom (ASTM) files S-1 for a full marketed follow-on with no warrants …http://www.scimitarequity.com/blog/2013/04/29/aastrom-astm-files-s-1-for-a-full-marketed-follow-on-with-no-warrants
- Aastrom Biosciences (ASTM) is DOWN… -$0.0649 or -9.41% at $0.6251 with a higher than usual 539.1 K volume at mid-day. The 50 and 200 day moving averages are at $0.91 and $1.24.
- BioLife Solutions (OTC: BLFS) – is FLAT…at $0.29 with share volume of 8 K at mid-day, compared to 1.2 K Friday. BLFS is growing its business while keeping high growth as the regenerative medicine market opportunity develops. BLFS hold the leading supplier position for pre-formulated, clinical grade biopreservation media products. The 50 and 200 day moving averages are at $0.30 and $0.31 respectively. The float is only 19.02 M as compared to outstanding shares of 69.67 M. BLFS is UP +200% for the year – a STRONG BUY.
- Cytori (CYTX) …is up…+$0.02 or +0.74% …at $2.73, with today’s mid-day trading range of $2..68 – $2.77 and a 44.3 K share volume. The 50 and 200 day moving averages stand at $2.61 and $3.06 respectively. A BUY.
- Cytomedix (OTC: CMXI) is DOWN… -$0.02 or -3.92% at $0.49, with a trading range of $0.49 – $0.51 and moderate volume of 135.6 K shares compared to the close of $0.51 and moderate volume of 166.8 K shares. The 50 day and 200 day moving averages are at $0.51 and $0.66 respectively. Visibility is still an issue but the financing got done! Ranked a BUY with a 3-6 month target of $0.85 to $1.00!
- NeoStem (NYSE MKT: NBS) is DOWN -0.01 or -0.94%…at $0.63 with a moderately high trading volume of 539.9 K at mid-day. Both the trending 50 and 200 day moving averages remain at $0.65 and $0.64 respectively. Reiterating, to be STEADY in this market could be considered a small miracle … in comparison to this sector and the market! NBS continues a “BUY”!
- Medistem (PINK: MEDS) is DOWN…-$0.25 or -23.81% at $0.80 … with no real news and 200 share volume. MEDS needs to generate some significance to differentiate itself and forward … any visibility standing… A very thinly or no trading volume stock. A HOLD.
- Neuralstem, Inc. (NYSE MKT:CUR) presented final data on the intraspinal delivery method employed in its NSI-566 PI trial to treat amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease) at the American Association of Neurological Surgeons Annual Meeting. In a presentation called “Intraspinal Stem Cell Transplantation in ALS, A Phase I Trial: Cervical Microinjection Safety Outcomes,” Jonathan Patrick Riley, MD, of the Department of Neurological Surgery at Emory University, in Atlanta, GA, presented data from all 18 procedures, in 15 patients, treated in PI. The study found that none of the patients experienced neurological worsening from injections into either the upper (cervical) or lower (lumbar) region of the back, nor was there any evidence of spinal cord injury. The cells also appeared to be safe with no evidence of toxicity. Researchers further noted that, even in the vulnerable ALS spinal cord, serial injections were well-tolerated. They concluded that the approach of starting in the lower region of the spine, where the potential risk to the patient was less, and then progressing upwards, might not be required in future trials, and that this intraspinal delivery technique is an option for treating other neurodegenerative and traumatic spinal cord disorders.
- Fibrocell’s (OTC: FCSC) LAVIV® (azficel-T) was recognized as the Silver Winner in aesthetics of the science/medical category at the 2013 Edison Awards Ceremony and Gala in Chicago. LAVIV is the first and only autologous cellular product approved by the FDA to improve the appearance of moderate to severe nasolabial folds (smile lines) in adults. The distinguished Edison Awards symbolize the persistence and excellence personified by Thomas Alva Edison, inspiring creative minds to remain in the forefront of innovation, creativity and ingenuity in the global economy.
- Harvard Bioscience (HBIO) will announce results for its first quarter ended March 31, 2013 before market trading hours on Thursday, May 2, 2013. A conference call to discuss the company’s first quarter ended March 31, 2013 financial results is scheduled for Thursday, May 2, 2013 at 11:00 a.m. Boston time. In addition, management may answer questions concerning business and financial developments and trends, the Company’s view on earnings forecasts, update on its regenerative medicine device business, and other business and financial matters affecting the Company. Some of the information to be presented on the call or provided in response to questions may contain information that has not previously been disclosed. The conference call will be simultaneously broadcast over the Internet and can be accessed through the Harvard Bioscience, Inc. website. To listen to the conference call, log on to www.harvardbioscience.com and click on the Earnings Call icon. Financial and other statistical information presented on the call, including the HBIO earnings release, will also be available on the investor relations section of thewebsite. Click on the investor relations button and then click on the press release or webcast icon, as appropriate. If you are unable to listen to the live webcast, the call will be archived in the investor relations section of the website. The live conference call is also accessible by dialing toll-free 877-303-7611, or toll 970-315-0445, and referencing the pass code of “46125296″.
- Pluristem (PSTI) said independent researchers from the Queensland Lung Transplant Service at the University of Queensland, Australia demonstrated maintained cell blood flow and no adverse reactions after PSTI’s PLX (Placental eXpanded) was infused in a human lung model of pulmonary arterial hypertension (PAH). The findings were presented on April 25, 2013 at the 33rd Annual Meeting and Scientific Sessions of the International Society of Heart and Lung Transplantation (ISHLT) in Montreal, Canada. The presentation and poster entitled “Safety of a Mesenchymal-like Adherent Stromal Cell (PLX-PAD) in a Human Model of Pulmonary Arterial Hypertension (PAH)” are available at Pluristem’s website: http://www.pluristem.com/investors/ for the next 30 days.
- Cancer Treatment Centers of America (CTCA) appointmented Istvan Redei, MD, as National Director of Stem Cell Transplant and Cell Therapy. Dr. Redei, is based at the CTCA Midwestern Regional Medical Center in Zion, Illinois where he continues to serve as the Director of Stem Cell Therapy and Cell Therapy Program. Since joining CTCA he and his team have been responsible for treating over 700 analytic hematologic patients and performing nearly 200 transplant procedures.